1NM-PP1 Treatment of Mice Infected with Toxoplasma gondii

J Vet Med Sci. 2011 Jun 16. [Epub ahead of print]

1NM-PP1 Treatment of Mice Infected with Toxoplasma gondii

Sugi T, Kato K, Kobayashi K, Kurokawa H, Takemae H, Haiyan G, Recuenco FC, Iwanaga T, Horimoto T, Akashi H.
SourceDepartment of Veterinary Microbiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo.

Abstract
Bumped kinase inhibitors (BKIs) target analog-sensitive kinases, which the genomes of mammals rarely encode. Previously, we demonstrated that a BKI effectively suppressed the in vitro replication of Toxoplasma gondii, the causative pathogen of toxoplasmosis, by targeting T. gondii calcium-dependent protein kinase 1 (TgCDPK1) (Eukaryotic Cell, 9:667-670). Here, we examined whether the BKI 1NM-PP1 reduced parasite replication in vivo. A high dose of 1NM-PP1, by intraperitoneal injection, just before the parasite inoculation effectively reduced the parasite load in the brains, livers, and lungs of T. gondii-infected mice, however, a low dose of 1NM-PP1 with oral administration didn't change the survival rates of infected mice.

PMID:21685719[PubMed - as supplied by publisher]